Transcode Therapeutics

Transcode Therapeutics Net Income

The Net Income of Transcode Therapeutics (RNAZ) as of Oct 18, 2026 is -34.66 M USD. In the previous year, Net Income was -16.75 M USD — a change of 106.87% (lower).

Net Income

-34.66 MUSD

YoY

106.87%

Last updated:

In 2025, Transcode Therapeutics's profit amounted to -34.66 M USD, a 106.87% increase from the -16.75 M USD profit recorded in the previous year.

The Transcode Therapeutics Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
-18.55 M USD
Jan 1, 2024
-16.75 M USD
Jan 1, 2025
-34.66 M USD
Jan 1, 2026 (e)
-294,400.00 USD
Jan 1, 2027 (e)
-225,216.00 USD
Jan 1, 2028 (e)
-581,808.00 USD
Jan 1, 2029 (e)
-544,272.00 USD
Jan 1, 2030 (e)
-319,056.00 USD
The Transcode Therapeutics Net Income history
YEARNet IncomeYoY
est-319,056.00USD-41.38%
est-544,272.00USD-6.45%
est-581,808.00USD+158.33%
est-225,216.00USD-23.50%
est-294,400.00USD-99.15%
-34.66 MUSD+106.87%
-16.75 MUSD-9.66%
-18.55 MUSD+5.59%
-17.56 MUSD+156.67%
-6.84 MUSD+191.97%
-2.34 MUSD+286.01%
-607,212.00USD+33.91%
-453,440.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transcode Therapeutics Revenue

Transcode Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-19.42 M USD
-18.55 M USD
Jan 1, 2024
0.00 USD
-16.73 M USD
-16.75 M USD
Jan 1, 2025
0.00 USD
-27.98 M USD
-34.66 M USD
Jan 1, 2026 (e)
0.00 USD
-16.73 M USD
-294,400.00 USD
Jan 1, 2027 (e)
0.00 USD
-23.36 M USD
-225,216.00 USD
Jan 1, 2028 (e)
10.10 M USD
-26.72 M USD
-581,808.00 USD
Jan 1, 2029 (e)
28.36 M USD
-25.09 M USD
-544,272.00 USD
Jan 1, 2030 (e)
52.94 M USD
0.00 USD
-319,056.00 USD

Transcode Therapeutics Margins

Transcode Therapeutics stock margins

The Transcode Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Transcode Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Transcode Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
- %
- %
Jan 1, 2028 (e)
0.00 %
-264.65 %
-5.76 %
Jan 1, 2029 (e)
0.00 %
-88.49 %
-1.92 %
Jan 1, 2030 (e)
0.00 %
0.00 %
-0.60 %

Transcode Therapeutics Stock analysis

What does Transcode Therapeutics do? Transcode Therapeutics Inc is a biotechnology company headquartered in Boston, Massachusetts, operating within the health care sector. The firm specializes in the development and commercialization of diagnostic tools and therapeutic agents aimed at the detection and treatment of cancer. As of the latest available data, the organization employs nineteen full-time staff members, reflecting its position as a focused entity in the competitive biopharmaceutical landscape. The company made its public debut on the stock market on April 28, 2021, under the ticker symbol RNAZ, with an International Securities Identification Number of US89357L5012. Its strategic focus is heavily anchored in RNA-based technologies and novel mechanisms to combat malignancies across various tissue types. The company’s lead therapeutic candidate, TTX-MC138, is designed to target microRNA-10b, a critical regulator of metastatic cell viability. This target is implicated in a wide spectrum of cancers, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas and other solid tumors. By addressing this specific molecular pathway, Transcode Therapeutics aims to inhibit the spread and survival of cancer cells. In addition to its lead candidate, the firm maintains a robust pipeline of preclinical programs that explore diverse therapeutic modalities. One such program is TTX-siPDL1, which utilizes small interfering RNA to modulate programmed death-ligand 1, a protein often exploited by tumors to evade the immune system. Another preclinical initiative, TTX-siLIN28B, employs siRNA technology to inhibit the RNA-binding protein LIN28B, further expanding the company’s approach to gene silencing. Beyond solid tumor targets, Transcode Therapeutics is developing indication-agnostic programs that seek to activate the body’s natural defenses against cancer. TTX-RIGA is an RNA-based agonist of the retinoic acid-inducible gene I, designed to trigger innate immunity within the tumor microenvironment. The company also explores advanced genetic editing through TTX-CRISPR, a platform based on CRISPR/Cas9 technology intended to repair or eliminate cancer-causing genes directly within tumor cells. Furthermore, the firm is working on TTX-mRNA, a tumor-type specific platform for developing cancer vaccines. These vaccines are engineered to activate cytotoxic immune responses, thereby enhancing the body’s ability to recognize and destroy malignant cells. Through this multi-faceted approach combining diagnostics, therapeutics, and immune activation, Transcode Therapeutics Inc strives to provide innovative solutions for patients with various forms of cancer. Transcode Therapeutics is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Transcode Therapeutics's Profit Margins

The profit margins of Transcode Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Transcode Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Transcode Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Transcode Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Transcode Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Transcode Therapeutics stock

Net Income of Transcode Therapeutics is -34.66 M USD in 2025.

Net Income of Transcode Therapeutics changed from -16.75 M USD to -34.66 M USD, representing a 106.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Income Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Transcode Therapeutics historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Transcode Therapeutics

All Key Metrics — Transcode Therapeutics